documents
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
1,467 rows where agency_id = "DEA" sorted by posted_date descending
This data as json, CSV (advanced)
Suggested facets: subtype, posted_month, open_for_comment, withdrawn, posted_date (date), comment_start_date (date), comment_end_date (date), last_modified (date)
posted_year 20
document_type 5
- Notice 678
- Supporting & Related Material 307
- Rule 287
- Proposed Rule 175
- Other 20
agency_id 1
- DEA · 1,467 ✖
| id | agency_id | docket_id | title | document_type | subtype | posted_date ▲ | posted_year | posted_month | comment_start_date | comment_end_date | last_modified | fr_doc_num | open_for_comment | withdrawn | object_id |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DEA-2026-0399-0001 | DEA | Stepan Company (DEA 1676) DEA-2026-0399 | 2026-04969 | Notice | 2026-03-13T04:00:00Z | 2026 | 3 | 2026-03-13T04:00:00Z | 2026-05-13T03:59:59Z | 2026-03-13T15:08:50Z | 2026-04969 | 1 | 0 | 09000064b92124fa | |
| DEA-2026-0397-0001 | DEA | Lonza Tampa, LLC (DEA 1679) DEA-2026-0397 | 2026-04972 | Notice | 2026-03-13T04:00:00Z | 2026 | 3 | 2026-03-13T04:00:00Z | 2026-04-14T03:59:59Z | 2026-03-13T14:45:34Z | 2026-04972 | 1 | 0 | 09000064b9212c9d | |
| DEA-2026-0401-0001 | DEA | Patheon API Services Inc (DEA 1681) DEA-2026-0401 | 2026-04973 | Notice | 2026-03-13T04:00:00Z | 2026 | 3 | 2026-03-13T04:00:00Z | 2026-05-13T03:59:59Z | 2026-03-13T15:35:31Z | 2026-04973 | 1 | 0 | 09000064b92124fc | |
| DEA-2026-0398-0001 | DEA | Purisys, LLC (DEA 1677) DEA-2026-0398 | 2026-04970 | Notice | 2026-03-13T04:00:00Z | 2026 | 3 | 2026-03-13T04:00:00Z | 2026-04-14T03:59:59Z | 2026-03-13T14:56:07Z | 2026-04970 | 1 | 0 | 09000064b92124f9 | |
| DEA_FRDOC_0001-0508 | DEA | Recently Posted DEA Rules and Notices DEA_FRDOC_0001 | Designation of Propionyl Chloride as a List I Chemical | Rule | 2026-03-10T04:00:00Z | 2026 | 3 | 2026-03-10T04:00:00Z | 2026-03-10T16:55:22Z | 2026-04657 | 0 | 0 | 09000064b9206be3 | ||
| DEA-2026-0364-0001 | DEA | Sigma Aldrich Research (DEA 1642) DEA-2026-0364 | 2026-04655 | Notice | 2026-03-10T04:00:00Z | 2026 | 3 | 2026-03-10T04:00:00Z | 2026-05-12T03:59:59Z | 2026-03-10T15:16:01Z | 2026-04655 | 1 | 0 | 09000064b9206aa3 | |
| DEA-2026-0335-0001 | DEA | Patheon API Inc. (DEA 1671) DEA-2026-0335 | 2026-04305 | Notice | 2026-03-04T05:00:00Z | 2026 | 3 | 2026-03-04T05:00:00Z | 2026-04-04T03:59:59Z | 2026-03-04T18:09:28Z | 2026-04305 | 1 | 0 | 09000064b91ef642 | |
| DEA-2026-0331-0001 | DEA | Amneal Pharmaceuticals, LLC (I) (DEA 1667) DEA-2026-0331 | 2026-04289 | Notice | 2026-03-04T05:00:00Z | 2026 | 3 | 2026-03-04T05:00:00Z | 2026-04-04T03:59:59Z | 2026-03-04T17:25:29Z | 2026-04289 | 1 | 0 | 09000064b91edfee | |
| DEA-2026-0336-0001 | DEA | Restek Corporation (Bulk Manufacture) (DEA 1672) DEA-2026-0336 | 2026-04306 | Notice | 2026-03-04T05:00:00Z | 2026 | 3 | 2026-03-04T05:00:00Z | 2026-05-05T03:59:59Z | 2026-03-04T18:21:12Z | 2026-04306 | 1 | 0 | 09000064b91ef6b1 | |
| DEA-2026-0332-0001 | DEA | Catalent Greenville, Inc (I) (DEA 1668) DEA-2026-0332 | 2026-04296 | Notice | 2026-03-04T05:00:00Z | 2026 | 3 | 2026-03-04T05:00:00Z | 2026-04-04T03:59:59Z | 2026-03-04T17:35:12Z | 2026-04296 | 1 | 0 | 09000064b91eeb41 | |
| DEA-2026-0337-0001 | DEA | Parexel International, LLC (DEA 1673) DEA-2026-0337 | 2026-04308 | Notice | 2026-03-04T05:00:00Z | 2026 | 3 | 2026-03-04T05:00:00Z | 2026-04-04T03:59:59Z | 2026-03-04T18:34:04Z | 2026-04308 | 1 | 0 | 09000064b91ef6cd | |
| DEA-2026-0334-0001 | DEA | Restek Corporation (I) (DEA 1670) DEA-2026-0334 | 2026-04299 | Notice | 2026-03-04T05:00:00Z | 2026 | 3 | 2026-03-04T05:00:00Z | 2026-04-04T03:59:59Z | 2026-03-04T17:59:10Z | 2026-04299 | 1 | 0 | 09000064b91ef531 | |
| DEA-2026-0338-0001 | DEA | Maridose, LLC (I) (DEA 1674) DEA-2026-0338 | 2026-04307 | Notice | 2026-03-04T05:00:00Z | 2026 | 3 | 2026-03-04T05:00:00Z | 2026-04-04T03:59:59Z | 2026-03-04T18:44:47Z | 2026-04307 | 1 | 0 | 09000064b91ef6db | |
| DEA-2026-0333-0001 | DEA | Stephan Company (I) (DEA 1669) DEA-2026-0333 | 2026-04303 | Notice | 2026-03-04T05:00:00Z | 2026 | 3 | 2026-03-04T05:00:00Z | 2026-04-04T03:59:59Z | 2026-03-04T19:41:44Z | 2026-04303 | 1 | 0 | 09000064b91ef744 | |
| DEA_FRDOC_0001-0507 | DEA | Recently Posted DEA Rules and Notices DEA_FRDOC_0001 | Schedules of Controlled Substances: Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I of the Controlled Substances Act | Rule | 2026-03-02T05:00:00Z | 2026 | 3 | 2026-03-02T05:00:00Z | 2026-03-02T18:40:50Z | 2026-04112 | 0 | 0 | 09000064b91e8fdf | ||
| DEA-2026-0298-0001 | DEA | Scottsdale Research Institute (Bulk Manuf.). (DEA 1654) DEA-2026-0298 | 2026-02908 | Notice | 2026-02-13T05:00:00Z | 2026 | 2 | 2026-02-13T05:00:00Z | 2026-04-15T03:59:59Z | 2026-02-13T16:55:52Z | 2026-02908 | 1 | 0 | 09000064b91a975a | |
| DEA-2026-0301-0001 | DEA | S&B Pharma LLC DBA Norac Pharma (DEA 1661) DEA-2026-0301 | 2026-02914 | Notice | 2026-02-13T05:00:00Z | 2026 | 2 | 2026-02-13T05:00:00Z | 2026-03-17T03:59:59Z | 2026-02-13T17:33:21Z | 2026-02914 | 1 | 0 | 09000064b91aa585 | |
| DEA-2026-0299-0001 | DEA | Scottsdale Research Institute (DEA 1659) DEA-2026-0299 | 2026-02909 | Notice | 2026-02-13T05:00:00Z | 2026 | 2 | 2026-02-13T05:00:00Z | 2026-04-15T03:59:59Z | 2026-02-13T17:08:24Z | 2026-02909 | 1 | 0 | 09000064b91a93c0 | |
| DEA-2026-0300-0001 | DEA | Siemens Healthcare Diagnostics, Inc. (DEA 1650) DEA-2026-0300 | 2026-02911 | Notice | 2026-02-13T05:00:00Z | 2026 | 2 | 2026-02-13T05:00:00Z | 2026-04-15T03:59:59Z | 2026-02-13T17:22:11Z | 2026-02911 | 1 | 0 | 09000064b91aa295 | |
| DEA-2026-0265-0001 | DEA | S&B Pharma LLC DBA Norac Pharma (DEA 1658) DEA-2026-0265 | New Document created by Goodman, Myron Joseph (DEA) | Notice | 2026-02-05T05:00:00Z | 2026 | 2 | 2026-02-05T05:00:00Z | 2026-04-07T03:59:59Z | 2026-02-05T17:14:19Z | 2026-02232 | 1 | 0 | 09000064b918f95f | |
| DEA_FRDOC_0001-0506 | DEA | Recently Posted DEA Rules and Notices DEA_FRDOC_0001 | Registering Emergency Medical Services Agencies under the Protecting Patient Access to Emergency Medications Act of 2017 | Rule | 2026-02-05T05:00:00Z | 2026 | 2 | 2026-02-05T05:00:00Z | 2026-02-05T17:30:25Z | 2026-02288 | 0 | 0 | 09000064b919298b | ||
| DEA-2026-0232-0001 | DEA | Sterling Pharma USA LLC (DEA 1655) DEA-2026-0232 | 2026-02230 | Notice | 2026-02-04T05:00:00Z | 2026 | 2 | 2026-02-04T05:00:00Z | 2026-04-07T03:59:59Z | 2026-02-04T16:51:02Z | 2026-02230 | 1 | 0 | 09000064b918f523 | |
| DEA-2026-0202-0001 | DEA | Mylan Inc. (DEA 1653) DEA-2026-0202 | 2026-01947 | Notice | 2026-02-02T05:00:00Z | 2026 | 2 | 2026-02-02T05:00:00Z | 2026-03-05T04:59:59Z | 2026-02-02T17:29:25Z | 2026-01947 | 0 | 0 | 09000064b9189d44 | |
| DEA-2026-0201-0001 | DEA | Medi-Physics Inc. DBA GE Healthcare (DEA 1652) DEA-2026-0201 | 2026-01946 | Notice | 2026-02-02T05:00:00Z | 2026 | 2 | 2026-02-02T05:00:00Z | 2026-02-02T17:08:20Z | 0 | 0 | 09000064b918c18e | |||
| DEA-2026-0199-0001 | DEA | Promega Corporation (DEA 1649) DEA-2026-0199 | 2026-01940 | Notice | 2026-02-02T05:00:00Z | 2026 | 2 | 2026-02-02T05:00:00Z | 2026-04-04T03:59:59Z | 2026-02-02T16:32:26Z | 2026-01940 | 1 | 0 | 09000064b918b1d4 | |
| DEA-2026-0200-0001 | DEA | Sharp Clinical Services LLC (DEA 1651) DEA-2026-0200 | 2026-01944 | Notice | 2026-02-02T05:00:00Z | 2026 | 2 | 2026-02-02T05:00:00Z | 2026-03-05T04:59:59Z | 2026-02-02T16:57:28Z | 2026-01944 | 0 | 0 | 09000064b918b1d5 | |
| DEA-2026-0168-0001 | DEA | Mylan Pharmaceuticals Inc. (DEA 1643) DEA-2026-0168 | 2026-01072 | Notice | 2026-01-26T05:00:00Z | 2026 | 1 | 2026-01-26T05:00:00Z | 2026-02-21T04:59:59Z | 2026-01-31T13:14:08Z | 2026-01072 | 0 | 0 | 09000064b917ed7f | |
| DEA-2026-0166-0001 | DEA | Maridose LLC (DEA 1647) DEA-2026-0166 | 2026-01298 | Notice | 2026-01-26T05:00:00Z | 2026 | 1 | 2026-01-26T05:00:00Z | 2026-03-25T03:59:59Z | 2026-01-26T17:16:39Z | 2026-01298 | 1 | 0 | 09000064b9181325 | |
| DEA-2026-0167-0001 | DEA | Organic Consultants LLC DBA Cascade Chemistry (DEA 1648) DEA-2026-0167 | 2026-01305 | Notice | 2026-01-26T05:00:00Z | 2026 | 1 | 2026-01-26T05:00:00Z | 2026-03-25T03:59:59Z | 2026-01-26T17:40:22Z | 2026-01305 | 1 | 0 | 09000064b917d077 | |
| DEA-2026-0169-0001 | DEA | Siegfried USA, LLC. (DEA 1646) DEA-2026-0169 | 2026-01194 | Notice | 2026-01-26T05:00:00Z | 2026 | 1 | 2026-01-26T05:00:00Z | 2026-02-24T04:59:59Z | 2026-01-26T18:09:41Z | 2026-01194 | 0 | 0 | 09000064b9181f15 | |
| DEA-2023-0057-0003 | DEA | Definition of ‘‘Cannabimimetic Agents’’ and Assignment of an Administration Controlled Substances Code Number for All ‘‘Cannabimimetic Agents’’ (DEA368) DEA-2023-0057 | Definition of Cannabimimetic Agents and Assignment of an Administration Controlled Substances Code Number for all Cannabimimetic Agents | Rule | 2026-01-20T05:00:00Z | 2026 | 1 | 2026-01-20T05:00:00Z | 2026-01-20T23:44:45Z | 2026-00907 | 0 | 0 | 09000064b9161314 | ||
| DEA-2026-0133-0001 | DEA | Schedules of Controlled Substances: Placement of 2-Fluorodeschloroketamine in Schedule I (DEA1442) DEA-2026-0133 | Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I | Proposed Rule | 2026-01-20T05:00:00Z | 2026 | 1 | 2026-01-20T05:00:00Z | 2026-01-20T23:36:31Z | 2026-00954 | 0 | 0 | 09000064b916130f | ||
| DEA-2026-0133-0004 | DEA | Schedules of Controlled Substances: Placement of 2-Fluorodeschloroketamine in Schedule I (DEA1442) DEA-2026-0133 | DEA-1442 HHS Letter to DEA 06112025 | Supporting & Related Material | 2026-01-20T05:00:00Z | 2026 | 1 | 2026-01-20T23:39:08Z | 0 | 0 | 09000064b9162339 | ||||
| DEA-2026-0133-0003 | DEA | Schedules of Controlled Substances: Placement of 2-Fluorodeschloroketamine in Schedule I (DEA1442) DEA-2026-0133 | DEA-1442 DEA Letter to HHS 11012024 | Supporting & Related Material | 2026-01-20T05:00:00Z | 2026 | 1 | 2026-02-12T21:01:03Z | 0 | 1 | 09000064b9162338 | ||||
| DEA-2026-0133-0002 | DEA | Schedules of Controlled Substances: Placement of 2-Fluorodeschloroketamine in Schedule I (DEA1442) DEA-2026-0133 | DEA-1442 3-Factor Analysis 2-Fluorodeschloroketamine January 2026 | Supporting & Related Material | 2026-01-20T05:00:00Z | 2026 | 1 | 2026-01-20T23:39:02Z | 0 | 0 | 09000064b9162337 | ||||
| DEA-2026-0133-0005 | DEA | Schedules of Controlled Substances: Placement of 2-Fluorodeschloroketamine in Schedule I (DEA1442) DEA-2026-0133 | DEA-1442 HHS Letter to DEA 11082024 | Supporting & Related Material | 2026-01-20T05:00:00Z | 2026 | 1 | 2026-01-20T23:39:10Z | 0 | 0 | 09000064b916233a | ||||
| DEA-2026-0133-0006 | DEA | Schedules of Controlled Substances: Placement of 2-Fluorodeschloroketamine in Schedule I (DEA1442) DEA-2026-0133 | DEA-1442 DEA Letter to HHS 05282025 | Supporting & Related Material | 2026-01-20T05:00:00Z | 2026 | 1 | 2026-02-12T21:01:51Z | 0 | 1 | 09000064b916233b | ||||
| DEA-2026-0100-0001 | DEA | Siegfried USA, LLC (DEA 1633) DEA-2026-0100 | 2026-00833 | Notice | 2026-01-16T05:00:00Z | 2026 | 1 | 2026-01-16T05:00:00Z | 2026-03-18T03:59:59Z | 2026-01-16T19:59:07Z | 2026-00833 | 1 | 0 | 09000064b915c15e | |
| DEA-2025-0075-0014 | DEA | Placement of 4-Fluoroamphetamine in Schedule I (DEA1180) DEA-2025-0075 | Schedules of Controlled Substances: Placement of 4-Fluoroamphetamine in Schedule I | Rule | 2026-01-15T05:00:00Z | 2026 | 1 | 2026-01-15T05:00:00Z | 2026-01-16T20:17:00Z | 2026-00633 | 0 | 0 | 09000064b9152a07 | ||
| DEA-2025-0771-0002 | DEA | Benuvia Operations, LLC. (DEA 1629) DEA-2025-0771 | 2025-21720 | Notice | 2026-01-12T05:00:00Z | 2026 | 1 | 2026-01-12T05:00:00Z | 2026-01-31T04:59:59Z | 2026-01-12T17:18:50Z | 2025-21720 | 0 | 0 | 09000064b90a7f7f | |
| DEA-2024-0118-0004 | DEA | Schedules of Controlled Substances: Temporary Placement of N-Pyrrolidino Metonitazene and N-Pyrrolidino Protonitazene in Schedule I (DEA1337) DEA-2024-0118 | Schedules of Controlled Substances: Placement of N-Pyrrolidino Metonitazene and N-Pyrrolidino Protonitazene in Schedule I | Rule | 2026-01-12T05:00:00Z | 2026 | 1 | 2026-01-12T05:00:00Z | 2026-01-13T02:58:59Z | 2026-00362 | 0 | 0 | 09000064b913658f | ||
| DEA-2025-0951-0002 | DEA | Groff Health Inc. (DEA 1634) DEA-2025-0951 | New Document created by Goodman, Myron Joseph (DEA) | Notice | 2026-01-08T05:00:00Z | 2026 | 1 | 2026-01-08T05:00:00Z | 2026-01-08T17:58:45Z | 0 | 0 | 09000064b90f4023 | |||
| DEA-2026-0068-0001 | DEA | Curium US LLC (DEA 1605) DEA-2026-0068 | 2026-00129 | Notice | 2026-01-08T05:00:00Z | 2026 | 1 | 2026-01-08T05:00:00Z | 2026-02-10T04:59:59Z | 2026-01-09T02:07:10Z | 2026-00129 | 0 | 0 | 09000064b911c8ca | |
| DEA-2026-0069-0001 | DEA | Janssen Pharmaceuticals (DEA 1639) DEA-2026-0069 | 2026-00128 | Notice | 2026-01-08T05:00:00Z | 2026 | 1 | 2026-01-08T05:00:00Z | 2026-02-10T04:59:59Z | 2026-01-09T02:05:38Z | 2026-00128 | 0 | 0 | 09000064b911de5c | |
| DEA-2026-0067-0001 | DEA | Mylan Technologies Inc. (DEA 1626) DEA-2026-0067 | 2026-00130 | Notice | 2026-01-08T05:00:00Z | 2026 | 1 | 2026-01-08T05:00:00Z | 2026-02-10T04:59:59Z | 2026-01-17T13:22:53Z | 2026-00130 | 0 | 0 | 09000064b911de59 | |
| DEA-2026-0070-0001 | DEA | AndersonBrecon (DEA 1638) DEA-2026-0070 | 2026-00127 | Notice | 2026-01-08T05:00:00Z | 2026 | 1 | 2026-01-08T05:00:00Z | 2026-02-10T04:59:59Z | 2026-01-12T17:08:51Z | 2026-00127 | 0 | 0 | 09000064b911de60 | |
| DEA-2026-0068-0002 | DEA | Curium US LLC (DEA 1605) DEA-2026-0068 | 2026-00129 | Notice | 2026-01-08T05:00:00Z | 2026 | 1 | 2026-01-08T05:00:00Z | 2026-01-09T02:11:45Z | 2026-00129 | 0 | 0 | 09000064b911fce4 | ||
| DEA-2026-0071-0001 | DEA | National Center for Natural Products Research (DEA 1613) DEA-2026-0071 | 2025-23503 | Notice | 2026-01-08T05:00:00Z | 2026 | 1 | 2026-01-08T05:00:00Z | 2026-01-22T04:59:59Z | 2026-01-09T02:02:05Z | 2025-23503 | 0 | 0 | 09000064b911d8c2 | |
| DEA-2026-0035-0001 | DEA | IsoSciences, LLC (DEA 1640) DEA-2026-0035 | 2025-23621 | Notice | 2026-01-05T05:00:00Z | 2026 | 1 | 2026-01-05T05:00:00Z | 2026-02-21T04:59:59Z | 2026-01-09T02:17:01Z | 2025-23621 | 0 | 0 | 09000064b9118449 | |
| DEA-2026-0001-0001 | DEA | Halo Halo Pharmaceutical Inc. (1620) DEA-2026-0001 | 2025-21177 | Notice | 2026-01-05T05:00:00Z | 2026 | 1 | 2026-01-05T05:00:00Z | 2025-12-27T04:59:59Z | 2026-01-09T02:21:48Z | 2025-21177 | 0 | 0 | 09000064b9118974 | |
| DEA-2026-0036-0001 | DEA | Navinta (DEA 1636) DEA-2026-0036 | 2025-23621 | Notice | 2026-01-05T05:00:00Z | 2026 | 1 | 2026-01-05T05:00:00Z | 2026-02-21T04:59:59Z | 2026-01-09T02:14:31Z | 2025-23620 | 0 | 0 | 09000064b911957b | |
| DEA-2026-0002-0001 | DEA | Blue Rabbit Veterinary LLC (I)(DEA 1628) DEA-2026-0002 | 2025-21719 | Notice | 2026-01-05T05:00:00Z | 2026 | 1 | 2026-01-05T05:00:00Z | 2026-01-01T04:59:59Z | 2026-01-09T02:19:00Z | 2025-21719 | 0 | 0 | 09000064b9118a2f | |
| DEA-2026-0034-0001 | DEA | Myonex, LLC (I) DEA 1631 DEA-2026-0034 | 2025-23619 | Notice | 2026-01-05T05:00:00Z | 2026 | 1 | 2026-01-05T05:00:00Z | 2026-01-22T04:59:59Z | 2026-01-09T01:59:48Z | 2025-23619 | 0 | 0 | 09000064b9118427 | |
| DEA-2023-0029-41937 | DEA | Telemedicine Prescribing of Controlled Substances (DEA407) DEA-2023-0029 | Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications | Rule | 2025-12-31T05:00:00Z | 2025 | 12 | 2025-12-31T05:00:00Z | 2026-01-13T03:01:01Z | 2025-24123 | 0 | 0 | 09000064b9113f32 | ||
| DEA-2023-0147-0004 | DEA | Placement of N-Desethyl Isotonitazene and N-Piperidinyl Etonitazene in Schedule I (DEA1143) DEA-2023-0147 | Schedules of Controlled Substances: Placement of N-Desethyl Isotonitazene and N-Piperidinyl Etonitazene in Schedule I | Rule | 2025-12-23T05:00:00Z | 2025 | 12 | 2025-12-23T05:00:00Z | 2026-01-06T01:10:17Z | 2025-23717 | 0 | 0 | 09000064b91067de | ||
| DEA-2025-0952-0001 | DEA | Aveva Drug Delivery Systems, Inc. (DEA 1614) DEA-2025-0952 | 2025-23469 | Notice | 2025-12-19T05:00:00Z | 2025 | 12 | 2025-12-19T05:00:00Z | 2026-01-21T04:59:59Z | 2025-12-19T19:32:12Z | 2025-23469 | 0 | 0 | 09000064b90f4ec6 | |
| DEA-2025-0953-0001 | DEA | Janssen Pharmaceuticals, Inc. (DEA 1635) DEA-2025-0953 | 2025-23467 | Notice | 2025-12-19T05:00:00Z | 2025 | 12 | 2025-12-19T05:00:00Z | 2026-02-18T04:59:59Z | 2026-01-09T02:23:39Z | 2025-23467 | 0 | 0 | 09000064b90f4eeb | |
| DEA-2025-0951-0001 | DEA | Groff Health Inc. (DEA 1634) DEA-2025-0951 | 2025-23466 | Notice | 2025-12-19T05:00:00Z | 2025 | 12 | 2026-01-09T02:25:15Z | 0 | 1 | 09000064b90f4e72 | ||||
| DEA-2025-0954-0001 | DEA | Bright Green Corporation (DEA1612) DEA-2025-0954 | 2025-23468 | Notice | 2025-12-19T05:00:00Z | 2025 | 12 | 2025-12-19T05:00:00Z | 2026-01-21T04:59:59Z | 2025-12-19T19:57:02Z | 2025-23468 | 0 | 0 | 09000064b90f4f00 | |
| DEA-2025-0918-0003 | DEA | Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I of the Controlled Substances Act (DEA1604) DEA-2025-0918 | 251203 OASH to DEA draft letter 4 synthetic cannabinoids 8FA_signed 12032025 | Supporting & Related Material | 2025-12-18T05:00:00Z | 2025 | 12 | 2025-12-18T19:22:36Z | 0 | 0 | 09000064b90eed87 | ||||
| DEA-2025-0918-0005 | DEA | Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I of the Controlled Substances Act (DEA1604) DEA-2025-0918 | 4F-MDMB-BUTICA ADB-4en-PINACA 5F-EDMB-PICA MMB-FUBICA 8-Factor Analysis December 2025 DEA | Supporting & Related Material | 2025-12-18T05:00:00Z | 2025 | 12 | 2025-12-18T19:22:42Z | 0 | 0 | 09000064b90eed89 | ||||
| DEA-2025-0918-0004 | DEA | Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I of the Controlled Substances Act (DEA1604) DEA-2025-0918 | 4F-MDMB-BUTICA ADB-4en-PINACA 5F-EDMB-PICA MMB-FUBICA 8-Factor December 2025 HHS | Supporting & Related Material | 2025-12-18T05:00:00Z | 2025 | 12 | 2025-12-18T19:22:39Z | 0 | 0 | 09000064b90eed88 | ||||
| DEA-2025-0918-0002 | DEA | Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I of the Controlled Substances Act (DEA1604) DEA-2025-0918 | Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I | Proposed Rule | 2025-12-16T05:00:00Z | 2025 | 12 | 2025-12-16T05:00:00Z | 2026-01-16T04:59:59Z | 2025-12-23T10:00:13Z | 2025-22963 | 0 | 0 | 09000064b90da711 | |
| DEA-2025-0918-0001 | DEA | Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I of the Controlled Substances Act (DEA1604) DEA-2025-0918 | Schedules of Controlled Substances: Extension of Temporary Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I of the Controlled Substances Act | Rule | 2025-12-16T05:00:00Z | 2025 | 12 | 2025-12-16T05:00:00Z | 2025-12-16T21:28:16Z | 2025-22960 | 0 | 0 | 09000064b90da7df | ||
| DEA-2025-0885-0003 | DEA | Schedules of Controlled Substances: Placement of Bromazolam in Schedule I (DEA1420) DEA-2025-0885 | HHS letter to DEA Bromazolam 07102025 | Supporting & Related Material | 2025-12-15T05:00:00Z | 2025 | 12 | 2025-12-15T20:47:51Z | 0 | 0 | 09000064b90d40f8 | ||||
| DEA-2025-0885-0002 | DEA | Schedules of Controlled Substances: Placement of Bromazolam in Schedule I (DEA1420) DEA-2025-0885 | HHS letter to DEA Bromazolam 06282024 | Supporting & Related Material | 2025-12-15T05:00:00Z | 2025 | 12 | 2025-12-15T20:47:46Z | 0 | 0 | 09000064b90d40f6 | ||||
| DEA-2025-0885-0001 | DEA | Schedules of Controlled Substances: Placement of Bromazolam in Schedule I (DEA1420) DEA-2025-0885 | Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I | Proposed Rule | 2025-12-15T05:00:00Z | 2025 | 12 | 2025-12-15T05:00:00Z | 2025-12-15T20:45:21Z | 2025-22763 | 0 | 0 | 09000064b90d3470 | ||
| DEA-2025-0885-0004 | DEA | Schedules of Controlled Substances: Placement of Bromazolam in Schedule I (DEA1420) DEA-2025-0885 | DEA 3-Factor Analysis Bromazolam December 2025 | Supporting & Related Material | 2025-12-15T05:00:00Z | 2025 | 12 | 2025-12-15T20:47:54Z | 0 | 0 | 09000064b90d40f7 | ||||
| DEA-2025-0852-0005 | DEA | Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I (DEA1511) DEA-2025-0852 | HHS Letter to DEA cumyl-PEGACLONE_112024 | Supporting & Related Material | 2025-12-12T05:00:00Z | 2025 | 12 | 2025-12-13T02:46:04Z | 0 | 0 | 09000064b90cb028 | ||||
| DEA-2025-0852-0007 | DEA | Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I (DEA1511) DEA-2025-0852 | HHS Letter to DEA cumyl-PEGACLONE_112024 | Supporting & Related Material | 2025-12-12T05:00:00Z | 2025 | 12 | 2025-12-13T02:50:33Z | 0 | 0 | 09000064b90cb02a | ||||
| DEA-2025-0852-0006 | DEA | Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I (DEA1511) DEA-2025-0852 | CUMYL-PEGACLONE HHS 8 Factor Review | Supporting & Related Material | 2025-12-12T05:00:00Z | 2025 | 12 | 2025-12-13T02:50:28Z | 0 | 0 | 09000064b90cb029 | ||||
| DEA-2025-0852-0008 | DEA | Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I (DEA1511) DEA-2025-0852 | CUMYL PEGACLONE DEA 8-Factor Analysis_1222025 | Supporting & Related Material | 2025-12-12T05:00:00Z | 2025 | 12 | 2025-12-13T02:50:36Z | 0 | 0 | 09000064b90cb02b | ||||
| DEA-2025-0852-0004 | DEA | Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I (DEA1511) DEA-2025-0852 | CUMYL-PEGACLONE HHS 8 Factor Review | Supporting & Related Material | 2025-12-12T05:00:00Z | 2025 | 12 | 2025-12-13T02:46:02Z | 0 | 0 | 09000064b90cb027 | ||||
| DEA-2025-0852-0003 | DEA | Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I (DEA1511) DEA-2025-0852 | CUMYL PEGACLONE DEA 8-Factor Analysis_1222025 | Supporting & Related Material | 2025-12-12T05:00:00Z | 2025 | 12 | 2025-12-13T02:45:59Z | 0 | 0 | 09000064b90cb026 | ||||
| DEA-2025-0555-0055 | DEA | Schedules of Controlled Substances: Placement of MDMB-4-PINACA in Schedule I (DEA1356) DEA-2025-0555 | Schedules of Controlled Substances: Extension of Temporary Placement of MDMB-4en-PINACA in Schedule I | Rule | 2025-12-11T05:00:00Z | 2025 | 12 | 2025-12-11T05:00:00Z | 2025-12-11T19:41:46Z | 2025-22540 | 0 | 0 | 09000064b90c55b5 | ||
| DEA-2025-0852-0002 | DEA | Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I (DEA1511) DEA-2025-0852 | Schedules of Controlled Substances: Extension of Temporary Placement of CUMYL-PEGACLONE in Schedule I | Rule | 2025-12-11T05:00:00Z | 2025 | 12 | 2025-12-11T05:00:00Z | 2025-12-11T19:46:09Z | 2025-22496 | 0 | 0 | 09000064b90c55b7 | ||
| DEA-2025-0852-0001 | DEA | Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I (DEA1511) DEA-2025-0852 | Schedules of Controlled Substances: Placement of Cumyl-Pegaclone in Schedule I | Proposed Rule | 2025-12-11T05:00:00Z | 2025 | 12 | 2025-12-11T05:00:00Z | 2026-01-13T04:59:59Z | 2025-12-24T10:00:21Z | 2025-22495 | 0 | 0 | 09000064b90c30e5 | |
| DEA-2025-0820-0001 | DEA | Kinetochem, LLC (Bulk. Manuf) (DEA 1625) DEA-2025-0820 | 2025-21790 | Notice | 2025-12-03T05:00:00Z | 2025 | 12 | 2025-12-03T05:00:00Z | 2025-02-04T04:59:59Z | 2025-12-03T19:44:43Z | 2025-21790 | 0 | 0 | 09000064b90ab305 | |
| DEA-2025-0687-0001 | DEA | Bulk Manufacturer of Controlled Substances Application: Noramco DEA 1618 DEA-2025-0687 | 2025-21192 (1) | Notice | 2025-12-01T05:00:00Z | 2025 | 12 | 2025-12-01T05:00:00Z | 2025-12-01T18:33:33Z | 0 | 0 | 09000064b90a17a3 | |||
| DEA-2025-0762-0001 | DEA | NSI Lab Solutions, LLC. (DEA 1608) DEA-2025-0762 | 2025-21180 | Notice | 2025-12-01T05:00:00Z | 2025 | 12 | 2025-12-01T05:00:00Z | 2025-12-27T04:59:59Z | 2025-12-01T23:13:28Z | 2025-21180 | 0 | 0 | 09000064b90a54c2 | |
| DEA-2025-0770-0001 | DEA | National Center for Natural Products Research (DEA 1621) DEA-2025-0770 | 2025-21190 | Notice | 2025-12-01T05:00:00Z | 2025 | 12 | 2025-12-01T05:00:00Z | 2026-01-27T04:59:59Z | 2025-12-02T00:40:21Z | 2025-21190 | 0 | 0 | 09000064b90a7f1d | |
| DEA-2025-0774-0001 | DEA | Invizyne Technologies, Inc. (DEA 1630) DEA-2025-0774 | 2025-21724 | Notice | 2025-12-01T05:00:00Z | 2025 | 12 | 2025-12-01T05:00:00Z | 2026-01-31T04:59:59Z | 2025-12-02T01:23:44Z | 2025-21724 | 0 | 0 | 09000064b90a8065 | |
| DEA-2025-0772-0001 | DEA | Irvine Labs (DEA 1627) DEA-2025-0772 | 2025-21187 | Notice | 2025-12-01T05:00:00Z | 2025 | 12 | 2025-12-01T05:00:00Z | 2026-01-27T04:59:59Z | 2025-12-02T01:09:04Z | 2025-21187 | 0 | 0 | 09000064b90a7fa4 | |
| DEA-2025-0763-0001 | DEA | VHG Labs DBA LGC Standards (DEA 1609) DEA-2025-0763 | 2025-21181 | Notice | 2025-12-01T05:00:00Z | 2025 | 12 | 2025-12-01T05:00:00Z | 2025-12-27T04:59:59Z | 2025-12-05T10:00:17Z | 2025-21181 | 0 | 0 | 09000064b90a54dc | |
| DEA-2025-0757-0001 | DEA | Irvine Labs (DEA 1616) DEA-2025-0757 | 2025-21175 | Notice | 2025-12-01T05:00:00Z | 2025 | 12 | 2025-12-01T05:00:00Z | 2025-12-27T04:59:59Z | 2025-12-01T21:24:06Z | 2025-21175 | 0 | 0 | 09000064b90a6a09 | |
| DEA-2025-0761-0001 | DEA | Caligor Coghlan Pharma Services (I) (DEA 1606) DEA-2025-0761 | 2025-21179 | Notice | 2025-12-01T05:00:00Z | 2025 | 12 | 2025-12-01T05:00:00Z | 2025-12-27T04:59:59Z | 2025-12-01T22:02:52Z | 2025-21179 | 0 | 0 | 09000064b90a67c5 | |
| DEA-2025-0769-0001 | DEA | Fisher Clinical Services, Inc. (DEA 1602) DEA-2025-0769 | 2025-21189 | Notice | 2025-12-01T05:00:00Z | 2025 | 12 | 2025-12-01T05:00:00Z | 2025-12-27T04:59:59Z | 2025-12-02T00:34:28Z | 2025-21189 | 0 | 0 | 09000064b90a7f00 | |
| DEA-2025-0768-0001 | DEA | Organix Chemistry Solutions, LLC (DEA 1624) DEA-2025-0768 | 2025-21186 | Notice | 2025-12-01T05:00:00Z | 2025 | 12 | 2025-12-01T05:00:00Z | 2026-01-27T04:59:59Z | 2025-12-02T00:15:42Z | 2025-21186 | 0 | 0 | 09000064b90a67c7 | |
| DEA-2025-0764-0001 | DEA | Groff NA Hemplex LLC (DEA 1610) DEA-2025-0764 | 2025-21182 | Notice | 2025-12-01T05:00:00Z | 2025 | 12 | 2025-12-01T05:00:00Z | 2026-01-27T04:59:59Z | 2025-12-01T23:36:37Z | 2025-21182 | 0 | 0 | 09000064b90a54df | |
| DEA-2025-0773-0001 | DEA | Invizyne Technologies, Inc. (DEA 1630) DEA-2025-0773 | 2025-21724 | Notice | 2025-12-01T05:00:00Z | 2025 | 12 | 2025-12-01T05:00:00Z | 2026-01-31T04:59:59Z | 2025-12-02T01:15:20Z | 2025-21724 | 0 | 0 | 09000064b90a7fc6 | |
| DEA-2025-0765-0001 | DEA | Cayman Chemical Company (DEA 1593) DEA-2025-0765 | 2025-21183 | Notice | 2025-12-01T05:00:00Z | 2025 | 12 | 2025-12-01T05:00:00Z | 2026-01-27T04:59:59Z | 2025-12-01T23:43:27Z | 2025-21183 | 0 | 0 | 09000064b90a814e | |
| DEA-2025-0753-0001 | DEA | Importer of Controlled Substances Application: Benuvia Operations, LLC (DEA 1619) DEA-2025-0753 | 2025-21173 | Notice | 2025-12-01T05:00:00Z | 2025 | 12 | 2025-11-26T05:00:00Z | 2025-12-27T04:59:59Z | 2025-12-01T20:28:41Z | 2025-21173 | 0 | 0 | 09000064b90a6905 | |
| DEA-2025-0760-0001 | DEA | Siegfried Grafton, Inc. (DEA 1601) DEA-2025-0760 | 2025-21178 | Notice | 2025-12-01T05:00:00Z | 2025 | 12 | 2025-12-01T05:00:00Z | 2025-12-27T04:59:59Z | 2025-12-01T21:55:42Z | 2025-21178 | 0 | 0 | 09000064b90a67c1 | |
| DEA-2025-0767-0001 | DEA | Siegfried Grafton, Inc. (DEA 1607) DEA-2025-0767 | 2025-21185 | Notice | 2025-12-01T05:00:00Z | 2025 | 12 | 2025-12-01T05:00:00Z | 2026-01-27T04:59:59Z | 2025-12-02T00:03:58Z | 2025-21185 | 0 | 0 | 09000064b90a7016 | |
| DEA-2025-0759-0001 | DEA | Organic Standards Solutions International, LLC (DEA 1617) DEA-2025-0759 | 2025-21176 | Notice | 2025-12-01T05:00:00Z | 2025 | 12 | 2025-12-01T05:00:00Z | 2025-12-27T04:59:59Z | 2025-12-01T21:42:35Z | 2025-21176 | 0 | 0 | 09000064b90a6788 | |
| DEA-2025-0720-0001 | DEA | Importer of Controlled Substances Application: Noramco DEA 1622 DEA-2025-0720 | 2025-21191 | Notice | 2025-12-01T05:00:00Z | 2025 | 12 | 2025-12-01T05:00:00Z | 2025-12-27T04:59:59Z | 2025-12-01T20:12:52Z | DEA-2025-0720 | 0 | 0 | 09000064b90a5893 | |
| DEA-2025-0756-0001 | DEA | Irvine Labs Inc. (M) (DEA 1615) DEA-2025-0756 | 2025-21174 | Notice | 2025-12-01T05:00:00Z | 2025 | 12 | 2025-12-01T05:00:00Z | 2026-01-27T04:59:59Z | 2025-12-01T21:10:37Z | 2025-21174 | 0 | 0 | 09000064b90a69de | |
| DEA-2025-0755-0001 | DEA | Irvine Labs Inc. (M) (DEA 1615) DEA-2025-0755 | 2025-21174 | Notice | 2025-12-01T05:00:00Z | 2025 | 12 | 2025-12-01T05:00:00Z | 2026-01-27T04:59:59Z | 2025-12-01T20:45:50Z | 2025-21174 | 0 | 0 | 09000064b90a6996 | |
| DEA-2025-0758-0001 | DEA | Organic Standards Solutions International, LLC (DEA 1617) DEA-2025-0758 | 2025-21176 | Notice | 2025-12-01T05:00:00Z | 2025 | 12 | 2025-12-01T05:00:00Z | 2025-12-27T04:59:59Z | 2025-12-01T21:33:01Z | DEA 2025-21176 | 0 | 0 | 09000064b90a6784 | |
| DEA-2025-0771-0001 | DEA | Benuvia Operations, LLC. (DEA 1629) DEA-2025-0771 | 2025-21720 | Notice | 2025-12-01T05:00:00Z | 2025 | 12 | 2025-12-01T05:00:00Z | 2026-01-31T04:59:59Z | 2025-12-02T00:50:08Z | 2025-21720 | 0 | 0 | 09000064b90a7f54 |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE documents (
id TEXT PRIMARY KEY,
agency_id TEXT,
docket_id TEXT REFERENCES dockets(id),
title TEXT,
document_type TEXT,
subtype TEXT,
posted_date TEXT,
posted_year INTEGER,
posted_month INTEGER,
comment_start_date TEXT,
comment_end_date TEXT,
last_modified TEXT,
fr_doc_num TEXT,
open_for_comment INTEGER,
withdrawn INTEGER,
object_id TEXT
);
CREATE INDEX idx_docs_agency ON documents(agency_id);
CREATE INDEX idx_docs_docket ON documents(docket_id);
CREATE INDEX idx_docs_date ON documents(posted_date);
CREATE INDEX idx_docs_year ON documents(posted_year);
CREATE INDEX idx_docs_type ON documents(document_type);
CREATE INDEX idx_docs_frnum ON documents(fr_doc_num);
CREATE INDEX idx_docs_comment_end ON documents(comment_end_date) WHERE comment_end_date IS NOT NULL AND withdrawn = 0;